These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8068481)

  • 1. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.
    Landmann R; Obrist R; Denz H; Ludwig C; Frost H; Wesp M; Rordorf C; Towbin H; Gygax D; Tarcsay L
    Biotherapy; 1993; 7(1):1-12. PubMed ID: 8068481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
    Liebes L; Walsh CM; Chachoua A; Oratz R; Richards D; Hochster H; Peace D; Marino D; Alba S; Le Sher D
    J Natl Cancer Inst; 1992 May; 84(9):694-9. PubMed ID: 1569602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T; Kleinerman ES
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
    Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
    J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
    Murray JL; Kleinerman ES; Cunningham JE; Tatom JR; Andrejcio K; Lepe-Zuniga J; Lamki LM; Rosenblum MG; Frost H; Gutterman JU
    J Clin Oncol; 1989 Dec; 7(12):1915-25. PubMed ID: 2479721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid).
    Fujimaki W; Itoh K; An T; Gano JB; Ross MI; Mansfield PF; Balch CM; Augustus LB; Karkevitch DD; Johnston D
    Cancer Biother; 1993; 8(4):307-18. PubMed ID: 7804372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
    Fujimaki W; Griffin JR; Kleinerman ES
    Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
    Urba WJ; Hartmann LC; Longo DL; Steis RG; Smith JW; Kedar I; Creekmore S; Sznol M; Conlon K; Kopp WC
    Cancer Res; 1990 May; 50(10):2979-86. PubMed ID: 1692252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
    Maeda M; Knowles RD; Kleinerman ES
    Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response.
    Galligioni E; Favaro D; Santarosa M; Quaia M; Spada A; Freschi A; Alberti D
    Clin Cancer Res; 1995 May; 1(5):493-9. PubMed ID: 9816008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.
    Venkatakrishnan K; Kramer WG; Synold TW; Goodman DB; Sides E; Oliva C
    Eur J Clin Pharmacol; 2012 Oct; 68(10):1347-55. PubMed ID: 22460239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
    Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
    Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects at adjuvant treatment of liver metastases in rat with RSU-1069 + microspheres, or liposomal MTP-PE.
    Wang L; Roos G; Stenram U
    Anticancer Res; 1995; 15(5B):2077-80. PubMed ID: 8572605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
    Ando K; Mori K; Corradini N; Redini F; Heymann D
    Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal MTP-PE: a promising new biologic response modifier.
    Gano JB; Kleinerman ES
    Oncol Nurs Forum; 1995 Jun; 22(5):809-16. PubMed ID: 7675688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.